Home » LIGAND TO PAY LILLY $20 MILLION FOR REMOVING ONTAK '05 ROYALTIES
LIGAND TO PAY LILLY $20 MILLION FOR REMOVING ONTAK '05 ROYALTIES
Ligand Pharmaceuticals exercised the first option to buy down a portion of the royalties payable to Eli Lilly on sales of Ligand's U.S. marketed cancer drug, Ontak. In a press release, Ligand said it will make a one-time cash payment of $20 million to Lilly in exchange for elimination of the Ontak royalties due to Lilly on net sales in the U.S. in 2005 and a reduced reverse-tiered royalty scale on net sales in the U.S. thereafter above a certain threshold.
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
23May
-
30May
-
13Jun
-
20Jun
-
21Oct